Teplensky et al., 2021 - Google Patents
Spherical nucleic acid vaccine structure markedly influences adaptive immune responses of clinically utilized prostate cancer targetsTeplensky et al., 2021
View HTML- Document ID
- 12084767985280822917
- Author
- Teplensky M
- Dittmar J
- Qin L
- Wang S
- Evangelopoulos M
- Zhang B
- Mirkin C
- Publication year
- Publication venue
- Advanced healthcare materials
External Links
Snippet
Cancer vaccines, which activate the immune system against a target antigen, are attractive for prostate cancer, where multiple upregulated protein targets are identified. However, many clinical trials implementing peptides targeting these proteins have yielded suboptimal …
- 229920002924 Spherical nucleic acid 0 title abstract description 105
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Teplensky et al. | Spherical nucleic acid vaccine structure markedly influences adaptive immune responses of clinically utilized prostate cancer targets | |
| Lhuillier et al. | Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control | |
| Wilson et al. | Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity | |
| JP5097400B2 (en) | Combined vaccine | |
| Chesson et al. | Antigenic peptide nanofibers elicit adjuvant-free CD8+ T cell responses | |
| Butterfield et al. | T-cell responses to HLA-A* 0201 immunodominant peptides derived from α-fetoprotein in patients with hepatocellular cancer | |
| Speiser et al. | Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients | |
| CN104220080B (en) | For reinforce CD4+T cell responses through modify epitope | |
| ES2626115T3 (en) | Immunogenic peptides and their use in transplantation | |
| Unanue et al. | The role of islet antigen presenting cells and the presentation of insulin in the initiation of autoimmune diabetes in the NOD mouse | |
| Li et al. | Elastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy | |
| US11759508B2 (en) | Antigenic peptides for treatment of B-cell malignancy | |
| CN103536915A (en) | Compositions and methods for the treatment of infections and tumors | |
| Durso et al. | A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses | |
| US20240075117A1 (en) | Microbiota sequence variants of tumor-related antigenic epitopes | |
| SA519410007B1 (en) | Peptides and methods for the treatment of diabetes | |
| JP2022541582A (en) | Compositions and methods for treating autoimmune disorders | |
| Cheng et al. | Recombination monophosphoryl lipid A-derived vacosome for the development of preventive cancer vaccines | |
| KR20200067862A (en) | Microbial sequence variants of tumor-associated antigen epitopes | |
| Patel et al. | Cowpea mosaic virus (CPMV)-based cancer testis antigen NY-ESO-1 vaccine elicits an antigen-specific cytotoxic T cell response | |
| Slezak et al. | Tumor cell-surface binding of immune stimulating polymeric glyco-adjuvant via cysteine-reactive pyridyl disulfide promotes antitumor immunity | |
| TW201726714A (en) | CDCA1 epitope peptides for TH1 cells and vaccines containing the same | |
| Doan et al. | Immunization-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection | |
| JP2017538754A (en) | Antigen delivery system | |
| ES2967314T3 (en) | Histone vaccines against cancer |